Product Overview
Fortune Healthcare manufactures Carboplatin Injection, a second-generation platinum-based chemotherapy agent, for use primarily in treating advanced ovarian cancer. Oncologists often prescribe it in combination with other chemotherapeutic agents such as cyclophosphamide, as the treating oncologist determines. It works by forming DNA cross-links that interfere with the replication of rapidly dividing cancer cells.
We supply this product as a premixed, sterile aqueous solution at a concentration of 10mg/mL, available in this listing as a 450mg/45mL vial (also available from the manufacturer in 50mg/5mL and 150mg/15mL vial sizes). Trained healthcare professionals must directly supervise its use, since we intend it solely for intravenous infusion in a hospital or specialist oncology setting.
Unlike some other platinum-based agents, Carboplatin does not require mandatory pre- or post-treatment hydration, which can simplify administration logistics for treating institutions. However, as a cytotoxic hazardous drug, it requires specific handling, preparation, and disposal precautions consistent with institutional cytotoxic drug protocols. Instead, hospitals, oncology day-care centers, cancer treatment institutions, and pharmaceutical distributors procure it — not retail or consumer-facing buyers.
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Carboplatin Injection |
| Strength | 450mg/45mL (10mg/mL concentration) |
| Also Available In | 50mg/5mL, 150mg/15mL (per manufacturer’s range) |
| Packaging Size | 1 vial |
| Dosage Form | Premixed sterile aqueous solution for IV infusion |
| Therapeutic Category | Anti-cancer / Cytotoxic chemotherapy (platinum analog) |
| Route of Administration | Intravenous infusion only |
| Storage | Store at 20–25°C (68–77°F); protect from light |
| Prescription Status | Prescription-only, hospital/specialist administration |
| Country of Origin | Made in India |
Composition Details
- Active ingredient: Carboplatin — 450mg per 45mL vial (10mg/mL)
- We supply it as a premixed aqueous solution, so it requires no reconstitution prior to further dilution
- Clinicians can further dilute it with 5% Dextrose (D5W) or 0.9% Sodium Chloride to concentrations as low as 0.5mg/mL, per standard preparation practice
Precautions & Warnings
- For hospital/specialist use only — pharmacies should never dispense this for self-administration or outpatient home use
- Hypersensitivity reactions: these can range from rash and urticaria to severe anaphylaxis; risk increases with repeated platinum exposure and particularly after 6 or more cycles, so staff should keep supportive equipment and medications for treating severe reactions available during administration
- Electrolyte disturbances: the drug may cause reductions in sodium, potassium, calcium, and magnesium levels; consequently, clinicians should monitor levels as clinically indicated
- Pregnancy and breastfeeding: doctors should avoid prescribing this, as it can cause fetal harm; therefore, patients should also avoid breastfeeding during treatment
- Handling precautions: because this is a cytotoxic agent, only trained personnel using appropriate protective equipment should handle it; additionally, pregnant healthcare workers should avoid handling this product
- Drug interactions: combining it with other myelosuppressive agents increases myelosuppression risk, so clinicians should use caution with nephrotoxic drugs as well
Overdose / Toxicity Management
Since trained clinical staff administer Carboplatin exclusively, “overdose” in this context refers to accidental clinical overdosing during preparation or administration rather than patient self-dosing. No known antidote exists. Instead, overdose primarily causes more severe and prolonged bone marrow suppression, with increased risk of infection and bleeding.
If staff suspect an overdose, they should treat it as a medical emergency and escalate it to senior clinical staff immediately. Meanwhile, the oncology team should direct supportive care — such as blood product transfusion and infection management — as clinically indicated.
Storage Instructions
- Store unopened vials at 20–25°C (68–77°F)
- Protect the vials from light
- Never freeze them
- Keep them in original packaging until ready for use in a clinical setting
- Store and dispose of them according to institutional cytotoxic/hazardous drug handling protocols
- Keep them out of reach of unauthorized personnel
Why Choose Fortune Healthcare’s Carboplatin Injection
- Quality-assured manufacturing: we produce it under GMP-compliant conditions for institutional and hospital supply
- Ready-to-use format: additionally, its premixed solution simplifies preparation workflows for treating institutions
- Institutional supply capability: as a result, it suits hospital procurement, tender supply, and distributor partnerships
- Export experience: finally, we supply it to international markets with documentation support for regulatory submissions
Frequently Asked Questions
It is a platinum-based chemotherapy medicine primarily used in the treatment of advanced ovarian cancer, typically as part of a combination treatment protocol determined by an oncologist
It is administered only by intravenous infusion, in a hospital or specialist oncology setting, typically over 15 minutes or longer, under the direct supervision of trained healthcare professionals.
The main dose-limiting risk is myelosuppression (reduced blood cell counts, particularly platelets), along with a risk of hypersensitivity reactions that increases with repeated cycles — both require close monitoring by the treating oncology team.
Unopened vials should be stored at 20–25°C (68–77°F), protected from light, and handled according to institutional cytotoxic drug storage protocols.
